Table 5 Pre- and post-surgery complications in mesh groups

Graft type

All

NAS meshes

Biologic meshes

All

NAS meshes

AS meshes

Mixed meshes

Biologic meshes

Mesh Exposition

6.1%

11%

0.34%

7.7% (0–34.1)

7.9% (0–34.1)

6.4% (0–12.9)

7.9% (0–30)

5.5% (0–16.7)

45 patients out of 733 in 13 trials(0% to 35.7%)

44 patients out of 398 in 9 trials (5% to 35.7%) [6, 9–12, 14, 15, 19, 20]

1 patient out of 298 in 5 trials (0% to 3.6%) [7, 13, 15, 17, 18]

98 trials n = 10076

84 trials n = 8747

2 trials n = 173

8 trials n = 786

4 trials n = 370

De novo urinary incontinence

6.3%

7.8%

1 patient out of 96 in 1 trial [15]

7% (0–24%)

6.6% (0%–24%)

0

5.6%

16.8%

26 patients out of 415 in 8 trials (0% to 40%)

25 patients out of 319 in 7 trials (0% to 40%) [6, 9, 11, 14–16, 20]

26 trials n = 3078

24 trials n = 2941

1 trialn = 36

1 trial n = 101

De novo Dyspareunia

5.3%

6.7%

None out of 35 patients in 1 trial [13]

9.2% (0–69)

9.2% (0–69)

3%

14.9% (4.5–27)

4.9% (0.9–10)

9 patients out of 170 in 4 trials (0% to 27.8%)

9 patients out of 135in 3 trials (4.6% to 27.8%) [10–12]

42 trials n = 3444

35 trials n = 3008

1 trial n = 90

3 trials n = 115

3 trials n = 231